Cargando…
Fatal limbic encephalitis as paraneoplastic neurological syndrome in a patient with lung adenocarcinoma positive for antiamphiphysin antibody after durvalumab treatment
A 69‐year‐old Japanese male with advanced lung adenocarcinoma developed neurological symptoms after chemoradiotherapy and durvalumab maintenance therapy. He was positive for serum antiamphiphysin antibody, which is rarely seen in patients with lung adenocarcinoma. Additionally, his brain magnetic re...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317590/ https://www.ncbi.nlm.nih.gov/pubmed/37253448 http://dx.doi.org/10.1111/1759-7714.14933 |
_version_ | 1785067898344046592 |
---|---|
author | Iwanaga, Yuto Kawaguchi, Takako Yamasaki, Kei Sato, Tomoki Kubo, Naoto Morimoto, Toshiki Isoshima, Yu Sasahara, Yosuke Orihashi, Takeshi Yatera, Kazuhiro |
author_facet | Iwanaga, Yuto Kawaguchi, Takako Yamasaki, Kei Sato, Tomoki Kubo, Naoto Morimoto, Toshiki Isoshima, Yu Sasahara, Yosuke Orihashi, Takeshi Yatera, Kazuhiro |
author_sort | Iwanaga, Yuto |
collection | PubMed |
description | A 69‐year‐old Japanese male with advanced lung adenocarcinoma developed neurological symptoms after chemoradiotherapy and durvalumab maintenance therapy. He was positive for serum antiamphiphysin antibody, which is rarely seen in patients with lung adenocarcinoma. Additionally, his brain magnetic resonance images showed limbic encephalitis which led to the diagnosis of classic paraneoplastic neurological syndrome (PNS). Immune checkpoint inhibitors (ICIs) activate T cells and may also activate antineuronal antibodies that cause PNS. Durvalumab, which is an ICI, may have led to antiamphiphysin antibody‐positive PNS in our patient. Treatment with systemic high‐dose methylprednisolone was unsuccessful and he died 2 months later. PNS should be considered as one of the differential diagnoses in patients with lung cancer and neurological symptoms during, or after, ICI treatment. |
format | Online Article Text |
id | pubmed-10317590 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-103175902023-07-04 Fatal limbic encephalitis as paraneoplastic neurological syndrome in a patient with lung adenocarcinoma positive for antiamphiphysin antibody after durvalumab treatment Iwanaga, Yuto Kawaguchi, Takako Yamasaki, Kei Sato, Tomoki Kubo, Naoto Morimoto, Toshiki Isoshima, Yu Sasahara, Yosuke Orihashi, Takeshi Yatera, Kazuhiro Thorac Cancer Case Reports A 69‐year‐old Japanese male with advanced lung adenocarcinoma developed neurological symptoms after chemoradiotherapy and durvalumab maintenance therapy. He was positive for serum antiamphiphysin antibody, which is rarely seen in patients with lung adenocarcinoma. Additionally, his brain magnetic resonance images showed limbic encephalitis which led to the diagnosis of classic paraneoplastic neurological syndrome (PNS). Immune checkpoint inhibitors (ICIs) activate T cells and may also activate antineuronal antibodies that cause PNS. Durvalumab, which is an ICI, may have led to antiamphiphysin antibody‐positive PNS in our patient. Treatment with systemic high‐dose methylprednisolone was unsuccessful and he died 2 months later. PNS should be considered as one of the differential diagnoses in patients with lung cancer and neurological symptoms during, or after, ICI treatment. John Wiley & Sons Australia, Ltd 2023-05-30 /pmc/articles/PMC10317590/ /pubmed/37253448 http://dx.doi.org/10.1111/1759-7714.14933 Text en © 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Case Reports Iwanaga, Yuto Kawaguchi, Takako Yamasaki, Kei Sato, Tomoki Kubo, Naoto Morimoto, Toshiki Isoshima, Yu Sasahara, Yosuke Orihashi, Takeshi Yatera, Kazuhiro Fatal limbic encephalitis as paraneoplastic neurological syndrome in a patient with lung adenocarcinoma positive for antiamphiphysin antibody after durvalumab treatment |
title | Fatal limbic encephalitis as paraneoplastic neurological syndrome in a patient with lung adenocarcinoma positive for antiamphiphysin antibody after durvalumab treatment |
title_full | Fatal limbic encephalitis as paraneoplastic neurological syndrome in a patient with lung adenocarcinoma positive for antiamphiphysin antibody after durvalumab treatment |
title_fullStr | Fatal limbic encephalitis as paraneoplastic neurological syndrome in a patient with lung adenocarcinoma positive for antiamphiphysin antibody after durvalumab treatment |
title_full_unstemmed | Fatal limbic encephalitis as paraneoplastic neurological syndrome in a patient with lung adenocarcinoma positive for antiamphiphysin antibody after durvalumab treatment |
title_short | Fatal limbic encephalitis as paraneoplastic neurological syndrome in a patient with lung adenocarcinoma positive for antiamphiphysin antibody after durvalumab treatment |
title_sort | fatal limbic encephalitis as paraneoplastic neurological syndrome in a patient with lung adenocarcinoma positive for antiamphiphysin antibody after durvalumab treatment |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317590/ https://www.ncbi.nlm.nih.gov/pubmed/37253448 http://dx.doi.org/10.1111/1759-7714.14933 |
work_keys_str_mv | AT iwanagayuto fatallimbicencephalitisasparaneoplasticneurologicalsyndromeinapatientwithlungadenocarcinomapositiveforantiamphiphysinantibodyafterdurvalumabtreatment AT kawaguchitakako fatallimbicencephalitisasparaneoplasticneurologicalsyndromeinapatientwithlungadenocarcinomapositiveforantiamphiphysinantibodyafterdurvalumabtreatment AT yamasakikei fatallimbicencephalitisasparaneoplasticneurologicalsyndromeinapatientwithlungadenocarcinomapositiveforantiamphiphysinantibodyafterdurvalumabtreatment AT satotomoki fatallimbicencephalitisasparaneoplasticneurologicalsyndromeinapatientwithlungadenocarcinomapositiveforantiamphiphysinantibodyafterdurvalumabtreatment AT kubonaoto fatallimbicencephalitisasparaneoplasticneurologicalsyndromeinapatientwithlungadenocarcinomapositiveforantiamphiphysinantibodyafterdurvalumabtreatment AT morimototoshiki fatallimbicencephalitisasparaneoplasticneurologicalsyndromeinapatientwithlungadenocarcinomapositiveforantiamphiphysinantibodyafterdurvalumabtreatment AT isoshimayu fatallimbicencephalitisasparaneoplasticneurologicalsyndromeinapatientwithlungadenocarcinomapositiveforantiamphiphysinantibodyafterdurvalumabtreatment AT sasaharayosuke fatallimbicencephalitisasparaneoplasticneurologicalsyndromeinapatientwithlungadenocarcinomapositiveforantiamphiphysinantibodyafterdurvalumabtreatment AT orihashitakeshi fatallimbicencephalitisasparaneoplasticneurologicalsyndromeinapatientwithlungadenocarcinomapositiveforantiamphiphysinantibodyafterdurvalumabtreatment AT yaterakazuhiro fatallimbicencephalitisasparaneoplasticneurologicalsyndromeinapatientwithlungadenocarcinomapositiveforantiamphiphysinantibodyafterdurvalumabtreatment |